Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bulkamid
- Development stage
- Unknown
- Lead developer
- Contura
- Modality
- Hydrogel Systems → Drug Delivery Systems
- Administration
- Intraurethral, Periurethral
01
Overview
Bulkamid is a urethral bulking agent used to treat stress urinary incontinence (SUI) in women. It is a transparent polyacrylamide hydrogel consisting of 97.5% water and 2.5% polyacrylamide that is injected into the submucosal tissue of the proximal urethra. The gel adds volume to the urethral wall, improving urethral coaptation and helping prevent urine leakage during physical activities. It remains in place without migrating or breaking down in the body, providing long-lasting relief.
- Brand names
- Bulkamid
- Other names
- Bulkamid HydrogelBulkamid Urethral Bulking System
Beyond the preview
Go deeper on Bulkamid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bulkamid.